Benzinga's Top Pre-Market NASDAQ Losers

Amedisys Inc AMED dipped 7.41% to $27.98 in the pre-market session. AMED shares have dropped 36.54% over the past 52 weeks, while the S&P 500 index has gained 22.09% in the same period. United Therapeutics Corporation UTHR dropped 6.71% to $58.49 in the pre-market trading. UTHR completed its FREEDOM-M Phase 3 trial of treprostinil diethanolamine (oral treprostinil). Exelixis Inc EXEL fell 2.39% to $10.63 in the pre-market session. EXEL reported interim data from an ongoing phase 2 adaptive randomized discontinuation trial of cabozantinib in patients with advanced solid tumors. Makita Corp MKTAY moved down 1.10% to $41.1619 in the pre-market session. MKTAY's trailing-twelve-month ROA is 7.25%. Read more from Benzinga's Markets.